Dexamethasone intravitreal implant for macular edema and some other rare indications in uveitis

In the present study, 110 eyes of 81 patients with uveitis who underwent intravitreal dexamethasone implant (IDI) injection and had a follow‑up at least 6 months between January, 2012 September, 2022, were retrospectively analyzed. A total 298 IDI injections administered (mean, 2.71±2.37; range, 1‑12). The mean age was 49.44±16.67 years (range, 15‑86 years). time after first 34.31±26.53 6‑115 months). total, 77 (95.1%) non‑infectious uveitis, while 4 (4.9%) received for uveitic macular edema in association infectious (1 patient acute retinal necrosis 3 systemic tuberculosis). injected under umbrella ganciclovir healed associated pseudophakic cystoid edema. (7.4%) prior to phacoemulsification surgery control possible post‑operative addition, (3.7%) Vogt‑Koyanagi‑Harada disease bilateral as therapy could not be due side‑effects treatment. 1 (1.2%) idiopathic vasculitis, aneurysms neuroretinitis treated both addition reduce ongoing inflammation. Of note, two (1.8%) simultaneous single anti‑vascular endothelial growth factor administration treatment unilateral extrafoveal neovascularization (one active serpiginous choroiditis one sympathetic ophthalmia). 68 (83.9%). Best‑corrected visual acuity improved from 0.69±0.64 0.60±0.76 logMAR final visit (P=0.008). Baseline central thickness (CMT) 499.74±229.60 µm 187‑1,187 µm) CMT 296.60±152.02 126‑848 µm). Intraocular pressure elevation requiring topical antiglaucomatous eye drops occurred 28 (25.5%). During period, glaucoma required 25 65 phakic (38.4%) phacoemulsification. Retinal detachment (0.9%), endophthalmitis transient hemorrhage three (2.7%) injections. On whole, study demonstrates that although is mostly employed edema, it can also cases intolerance, prophylaxis, great caution, selected involving